- PolyNovo (PNV) enrols its first patient for a trial evaluating the safety and efficiency of its NovoSorb SynPath product for the treatment of chronic diabetic foot ulcers
- As part of the randomised control trial, the company will test the product on 138 subjects
- Diabetic foot ulcers affect more than 300,000 Americans every year and account for more than US$9 billion (A$12.9 billion) in annual expenditures
- PolyNovo says given the number of people with diabetes and foot ulcers, recruitment is anticipated to be completed by April 2023
- PNV shares are down 0.24 per cent to $2.12 per share at 1:27 pm AEST
PolyNovo (PNV) has enrolled its first patient for a clinical trial evaluating the safety and efficiency of its NovoSorb SynPath product for the treatment of chronic diabetic foot ulcers.
SynPath is designed to promote organised healing by providing a porous network of biodegradable synthetic polymers, which acts as a template to support the cells involved in tissue repair.
The randomised control trial is on 138 subjects and will focus on the use of SynPath to treat chronic diabetic foot ulcers — open sores or wounds on the foot that occur in around 15 per cent of patients with diabetes.
Diabetic foot ulcers affect more than 300,000 Americans every year and account for more than US$9 billion (A$12.9 billion) in annual expenditures, according to PNV.
PolyNovo said given the number of people with diabetes and foot ulcers, recruitment was anticipated to be completed by April 2023.
The trial is being conducted over eight sites in the US, including The Center for Clinical Research in San Francisco and Barry University in Miami.
“We are thrilled to have initiated our trial utilising NovoSorb SynPath for the treatment of chronic diabetic foot ulcers. This critical milestone has us on the road to help more patients with non-healing chronic wounds and to further investigate the benefits of our novel technology for these wound types,” PolyNovo CEO Swami Raote said.
“SynPath is leveraging our successes in the acute care setting with NovoSorb BTM and
allows us to expand our offering to the outpatient setting for clinicians dedicated to changing the lives of their patients.”
PNV shares were down 0.24 per cent to $2.12 per share at 1:27 pm AEST.